Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: Correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance

Polish Journal of Pathology

Volumn 57, Issue 3, 2006, Pages 149-159

  Zavrides, Harris ^a,c   Zizi Sermpetzoglou, A ^a   Elemenoglou, I ^a   Papatheofanis, I ^a   Peros, G ^b   Athanasas, G ^b   Panousopoulos, D ^b  

^a TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE PRODUCT; HERMES ANTIGEN; KI 67 ANTIGEN; LAMININ; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; STAINING;

EID: 33845655620     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Allegra CJ, Paik S, Colangelo LH et al: Prognostic value of thymidylate synthase, ki-67, and p53 in patients with Dukes' B and C colon cancer: a national cancer institute-national surgical adjuvant breast and bowel project collaborative study. Journal of Clinical Oncology 2003, 21(2), 241-250.
2. Allegra CJ, Parr AL, Wold LE et al: Investigation of the prognostic and predictive value of thymidylate synthase, p53 and ki-67 in patients with locally advanced colon cancer. Journal of Clinical Oncology 2002, 20(7), 1735-1743.
3. Aoki A, Nakanishi Y, Akimoto S et al: Prognostic significance of laminin-5 γ2 chain expression in colorectal carcinoma: immunohistochemical analysis of 103 cases. Dis Colon Rectum 2002, 45, 1520-1527.
4. Barbareschi M, Caffo O, Veronese S et al: Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long term follow-up. Human Pathol 1996, 27, 1149-1155.
5. Baretton GB, Dielbold J, Christoforis G et al: Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 1996, 77, 255-264.
6. Bhatavdekar JM, Patel DD, Ghosh N et al: Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminats in patients with colorectal carcinoma. Dis Colon Rectum 1997, 40, 785-790.
7. Bosari S, Nonegnini L, Graziani D et al: Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas and adenocarcinomas. Hum Pathol 1995, 26(5), 534-540.
8. Bouzourene H, Gervaz P, Cerottini JP et al: P53 and ki-ras as prognostic factors for Dukes' stage B colorectal cancer. European Journal of Cancer 2000, 36, 1008-1015.
9. Flohill CC, Janssen PA, Bosman FT: Expression of bcl-2 protein in hyperplastic polyps, adenomas and carcinomas of the colon. J Pathol 1996, 178, 393-397.
10. Garrity MM, Burgart LJ, Mahoney MR et al: Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004, 22(9), 1572-1582.
11. Giatromanolaki A, Sivridis E, Stathopoulos GP et al: Bax protein expression in colorectal cancer. Association with p53, bcl-2 and patterns of relapse. Anticancer Research 2001, 21, 2253-2260.
12. Haier J, Naxralla M, Nicolson O: Cell surface molecules and their prognostic values in assessing colorectal carcinomas. Ann Surg 2000, 237, 11-24.
13. Ilyas M, Hao XP, Wilkinson K et al: Loss of bcl-2 expression correlates with tumour recurrence in colorectal cancer. Gut 1998, 43, 383-387.
14. Indinnimeo M, Cicchini C, Giamieri E, Stazi A, Mingazzini PL, Stipa V: Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Oncol Rep 2003, 10(6), 1875-1877.
15. Jeziorska M, Haboubi NY, Schofield PF et al: Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma. Int J Colored Dis 1994, 9, 141-148.
16. Joensuu H, Pylkkaanen I, Toikkanen S: Bcl-2 protein and long-term survival in breast cancer. Am J Pathol 1994, 145, 1191-1198.
17. Kahlenberg MS, Stoler DL, Rodriguez-Bigas MA et al: P53 tumour suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 2000, April 15, 88(8), 1814-1819.
18. Kaklamanis L, Savage A. Whitehouse R et al: Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. J Pathol 1998, 77, 1864-1867.
19. Kouraklis G, Kakisis J, Theoharis S, Tzonou A, Glivanou A, Raftopoulos J, Karatzas G: Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer. Dig Dis Sci 2003, 48(12), 2284-2289.
20. Lazaris Ach. Tzoumani AN, Thimara I et al: Immunohistochemical assessment of basement membrane components in colorectal cancer: prognostic implications. J Exp Clin Cancer Res 2003, 2(4), 599-606.
21. Manne U, Myers RB, Moron C et al: Prognostic significance of bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997, 74, 346-358.
22. Manne U, Weiss HL, Grizzle WE: Bcl-2 expression is associated with improved prognosis in patients with distal colorectal adenocarcinomas. Int J Cancer Pred Oncol 2000, 89, 423-430.
23. Miyasita T, Harigal M, Hanada M et al: Identification of a p53 dependent negative response element in the bcl-2 gene. Cancer Res 1994, 54, 3714-3717.
24. Mueller J, Mueller E, Hoepner I et al: Expression of bcl-2 and p53 in de novo and ex-addenoma colon carcinoma: a comparative immunohistochemical study. J Pathol 1996, 180, 259-265.
25. Pilotti S, Collini P, Rilke F et al: Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994, 172, 337-342.
26. Pricolo VE, Finkelstein SD, Hansen K, Cole BF, Kirby IB: Mutated p53 gene is an independent adverse predictor of survival on colon carcinoma. Arch Surg 1997, 132, 371-375.
27. Reed JC: Bcl-2 and the regulation of program cell death. J Cell Biol 1994, 124, 1-6.
28. Reerink O, Karrenbeld A, Plukker JT et al: Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. Anticancer Res 2004, 24(2c), 1217-1221.
29. Sinicrope FA, Ruan SB, Cleary KR et al: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995, 55, 237-241.
30. Sun XF, Bartik Z, Zhang H: Bcl-2 expression is a prognostic factor in the subgroups of patients with colorectal cancer. Int J Oncol 2003, 23(5), 1439-1443.
31. Tollenaar RA, van Krieken JH, van Slooten HJ et al: Immunohistochemical detection of p53 and bcl-2 in colorectal carcinoma: no evidence for prognostic significance. Brit J Cancer 1998, 77, 1842-1847.
32. Visca P, Del Nommo F, Botti C et al: Role and prognostic significance of CD44s expression in colorectal cancer. Anticancer Res 2002, 22(5), 2671-2675.
33. Watson AJM, Merrit AJ, Jones LS et al: Evidence for reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996, 73, 889-895.
34. Wilson JW, Nostro MC, Balzi M, Faraoni P, Cianchi F, Becciolini A, Potten CS: Bcl-w expression in colorectal cancer. Br J Cancer 2000, 82(1), 178-185.
35. World Health Organization: International Histological Classifications of Tumours: Histological Typing of Intestinal Tumours. Geneva. WHO, 1976.
36. Yank HB, Chow NH, Shey BS et al: The role of bcl-2 in the progression of the colorectal adenoma-carcinoma sequence. Anticancer Research 1999, 19, 727-730.
37. Yang JL, Hanley JR, Yu Y et al: In vivo overexpression of c-erB-2 oncoprotein in xenografts of mice implanted with human colon cancer lines. Anticancer Research 1997, 17, 3463-3468.
38. Yang J-L, Russell PJ, Crowe PJ et al: Higher expression of oncoprotein c-myc, c-neu, PCNA and p53 in metastasizing colorectal cancer (CRC) than in non-metastasizing colorectal CRC. Ann Surg Onco 1996, 3, 574-579.
39. Yang J-L, Russell PJ, Crowe PJ et al: Overexpression of c-erb-2 mRNA and/or c-neu oncoprotein is a predictor for metastases from colorectal cancer. Anticancer Res 1997, 17, 1023-1026.
40. Zalewski B, Famulski W, Sulkowska M, Sobaniec-Lotowska M, Piotrowski Z, Kisiekewski W, Sulkowski S: CD44 expression in colorectal cancer: an immunohistochemical study including coorelation with cathepsin D immunoreactivity and some tumour clinicopathological fetures. Folia Histochemica et Cyto Biologica 2001, 39(2), 152-153.
41. Zavrides H, Zizi-Sermpetzoglou A, Elemenoglou I et al: Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance. Pol J Pathol 2005, 56, 4, 179-185.